by Mat Dirjish
Abbott, a provider of diabetes and bio-wearable technologies, announces that the US Food and Drug Administration (FDA) authorizes its Libre Duo 10 Day system, which Abbott claims is the world’s first dual glucose‑ketone sensing technology. The bio-wearable alerts diabetics of rising ketones that can lead to diabetic ketoacidosis (DKA). Libre Duo 10 Day delivers real-time visibility into glucose levels necessary for diabetes management while also monitoring rising ketones in the background.
Reportedly, DKA is the most common hyperglycemic emergency for people with diabetes types 1/2 and hospital admissions for DKA have increased 55% over the past decade. Jennifer Sherr, M.D., Ph.D., and pediatric endocrinologist at Yale School of Medicine, explains, “I see how quickly DKA can develop and how often we miss early warning signs or opportunities to measure ketones. Abbott’s dual glucose-ketone system is meaningful because it collects ketone data in the background, helping to provide earlier awareness of rising ketone levels.”
Libre Duo 10 Day continuously monitors both glucose and ketone levels. Unlike blood or urine ketone tests, Libre’s sensors continuously track ketones and alert patients when ketones are rising. It offers diabetics ages two and up 10 days of wear and uses the latest-generation Libre app.
Additionally, Abbott is working with pump companies to enable automated insulin delivery (AID) systems to connect with Libre sensors. For greater enlightenment, peruse the Libre DUO 10 Day overview.
Mat Dirjish Online 